ImmunityBio, Inc. - Common Stock (IBRX)

Rosen Law Firm, a global investor rights law firm, announces it has filed a class action lawsuit on behalf of purchasers of the securities of ImmunityBio, Inc. (NASDAQ: IBRX) between January 19, 2026 and March 24, 2026, both dates inclusive (the “Class Period”). The lawsuit seeks to recover damages for ImmunityBio investors under the federal securities laws.

A diverse group of small- and mid-cap companies across defense technology, digital assets, biotech, energy, and education are drawing increased investor focus as new developments signal potential momentum heading into the next market cycle. From U.S. Marine Corps VR deployments to $1B debt reduction moves and biotech trial validation, multiple sectors are driving renewed investor attention.

NEW YORK, NY - March 26, 2026 (NEWMEDIAWIRE) - Kaplan Fox & Kilsheimer LLP is investigating potential securities violations against ImmunityBio, Inc. (“ImmunityBio” or the “Company”) (NASDAQ: IBRX).

Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations.

ImmunityBio, Inc. (NASDAQ: IBRX), a vertically integrated, commercial-stage immunotherapy company, today announced that based on the Independent Data Monitoring Committee (IDMC) review of the interim data, the committee recommended that the study is adequately powered to detect the pre-specified clinically meaningful difference in complete response (CR) rate between the experimental arm (ANKTIVA + BCG) and the control arm (BCG alone) at the protocol-specified power, in the randomized QUILT-2.005 (NCT02138734) study. The QUILT-2.005 study was designed to detect the pre-specified difference in CR rate between ANKTIVA® (nogapendekin alfa inbakicept-pmln) plus Bacillus Calmette-Guérin (BCG) and BCG alone in patients with BCG-naïve non-muscle invasive bladder cancer (NMIBC) with carcinoma in situ (CIS) with or without papillary disease, based on its review of the planned interim analysis.

NEW YORK, NY - March 24, 2026 (NEWMEDIAWIRE) - Kaplan Fox & Kilsheimer LLP is investigating potential securities violations against ImmunityBio, Inc. (“ImmunityBio” or the “Company”) (NASDAQ: IBRX).

Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations.

Why: Rosen Law Firm, a global investor rights law firm, announces an investigation of potential securities claims on behalf of shareholders of ImmunityBio, Inc. (NASDAQ: IBRX) resulting from allegations that ImmunityBio, Inc. may have issued materially misleading business information to the investing public.

ImmunityBio, Inc. (NASDAQ: IBRX), today announced that the Pharmaceutical Administration Bureau (ISAF) of the Macau Special Administrative Region of the People’s Republic of China has granted regulatory approval for ANKTIVA® (nogapendekin alfa inbakicept-pmln).

As capital rotation intensifies across micro- and small-cap equities in 2026, a new wave of sub-$10 stocks is gaining traction among investors seeking exposure to high-growth themes including immunotherapy breakthroughs, immersive XR technology, next-generation medical diagnostics, and AI-driven supply-chain security . Four companies— ImmunityBio (NASDAQ: IBRX), Virtuix (NASDAQ: VTIX), ENDRA Life Sciences (NASDAQ: NDRA), and SMX (NASDAQ: SMX) —are increasingly appearing on investor watchlists as catalysts build across multiple sectors.

ImmunityBio, Inc. (NASDAQ: IBRX), a commercial-stage immunotherapy company, today announced that the National Comprehensive Cancer Network (NCCN®) has updated its 2026 NCCN Clinical Practice Guidelines in Oncology for Bladder Cancer to include ANKTIVA® (nogapendekin alfa inbakicept-pmln) in combination with Bacillus Calmette-Guérin (BCG) for the treatment of patients with BCG-unresponsive non-muscle invasive bladder cancer (NMIBC) with papillary-only disease.

ImmunityBio (NASDAQ: IBRX), a commercial-stage immunotherapy company, today announced the successful completion of manufacturing engineering programs, NK2022 and NK2023, establishing a safe, reproducible, and scalable leukapheresis-to-manufacturing pathway for its autologous memory cytokine-enhanced natural killer (M-ceNK) cell therapy platform.

ImmunityBio, Inc. (NASDAQ: IBRX), today announced that it will host a live conference call at 1:30 p.m. Pacific Time on Tuesday, March 3, 2026, to provide a business update, including progress across the company’s clinical trial pipeline, and to review financial results for the year ended December 31, 2025.

ImmunityBio (NASDAQ: IBRX), a commercial-stage immunotherapy company, today announced completion of enrollment in its Phase 2 clinical trial evaluating ANKTIVA® (nogapendekin alfa inbakicept-pmln) plus Bacillus Calmette-Guérin (BCG) versus BCG alone in patients with BCG-naïve non-muscle invasive bladder cancer (NMIBC) carcinoma in situ (CIS), with or without papillary tumors.

ImmunityBio, Inc. (Nasdaq: IBRX), a commercial-stage biotechnology company pioneering next-generation immunotherapies, today announced that its Founder, Executive Chairman, and Global Chief Scientific and Medical Officer, Dr. Patrick Soon-Shiong, will participate as a featured speaker at "Cancer 2035: A Roadmap for the Future," a landmark summit co-hosted by the Milken Institute and the Richard Nixon Foundation in Washington, D.C. on February 23–24, 2026.

ImmunityBio, Inc. (NASDAQ: IBRX), a commercial-stage immunotherapy company, today announced full-year 2025 financial and operational highlights, including approximately $113 million in net product revenue for ANKTIVA, representing an approximately 700% increase year-over-year. The Company also reported a 750% increase in unit sales volume and a 20% quarter-over-quarter increase in net product revenue, demonstrating sustained commercial momentum. In parallel, ImmunityBio expanded its global regulatory footprint to 33 countries across four jurisdictions and secured the first approval for ANKTIVA in combination with checkpoint inhibitors for lung cancer.

ImmunityBio, Inc. (NASDAQ: IBRX), a commercial-stage immunotherapy company, today announced a partnership with Biopharma and Cigalah, two of the largest and most respected healthcare commercial and distribution companies in the Middle East, to launch ANKTIVA® (nogapendekin alfa inbakicept) in Saudi Arabia and, over time, across the broader MENA region.

ImmunityBio, Inc. (NASDAQ: IBRX), a commercial-stage immunotherapy company, today announced a partnership with Accord Healthcare to provide access to ANKTIVA® (nogapendekin alfa inbakicept) in combination with Bacillus Calmette-Guérin (BCG) for eligible patients in the European Union with BCG-unresponsive non-muscle invasive bladder cancer carcinoma in situ (NMIBC CIS), with or without papillary disease. ImmunityBio also announced the establishment of an Irish subsidiary in Dublin to support the company’s distribution and commercialization strategy throughout Europe.

ImmunityBio (NASDAQ: IBRX), a commercial-stage immunotherapy company, today announced that the European Commission has granted conditional marketing authorization for ANKTIVA® (nogapendekin alfa inbakicept) in combination with Bacillus Calmette-Guérin (BCG) for the treatment of adult patients with BCG-unresponsive non-muscle invasive bladder cancer (NMIBC) carcinoma in situ (CIS), with or without papillary tumors.

NEW YORK, Feb. 17, 2026 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of ImmunityBio, Inc. (“ImmunityBio” or the “Company”) (NASDAQ: IBRX).  Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980.

ImmunityBio, Inc. (NYSE: IBRX), a commercial stage immunotherapy company developing next generation therapies that drive immunological memory and restore immune competence, today announced that the Company held productive regulatory discussions with the Saudi Food and Drug Authority (SFDA) in Riyadh, convened under the Saudi-USA Biotech Alliance hosted by the Ministry of Investment of Saudi Arabia (MISA). The engagement advanced two regulatory priorities: (1) SFDA encouraged the Company to submit a regulatory package for its recombinant BCG (rBCG) to expand BCG access in Saudi Arabia and address the ongoing global BCG shortage, and (2) ImmunityBio and SFDA initiated discussions regarding the expansion of ANKTIVA® (nogapendekin alfa inbakicept) in combination with checkpoint inhibitors (CPIs) to additional tumor types in the CPI relapsed population.

ImmunityBio (NASDAQ: IBRX) is rapidly transforming into a commercial powerhouse, fueled by the explosive growth of its lead immunotherapy, ANKTIVA. Following a year of breakthrough regulatory wins and clinical milestones, the company has reported a staggering 700% year-over-year increase in preliminary net product revenue, reaching approximately $113 million for 2025.

NEW YORK, Feb. 03, 2026 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of ImmunityBio, Inc. (“ImmunityBio” or the “Company”) (NASDAQ: IBRX).  Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980.

ImmunityBio, Inc. (NASDAQ: IBRX), a commercial-stage immunotherapy company, today announced the launch of ResQ215B, a Phase 2 clinical study evaluating a novel chemotherapy-free and lymphodepletion-free combination immunotherapy in patients with indolent B-cell non-Hodgkin lymphoma (iNHL), including Waldenström’s Macroglobulinemia.

NEW YORK, Jan. 27, 2026 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of ImmunityBio, Inc. (“ImmunityBio” or the “Company”) (NASDAQ: IBRX).  Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980.